MedTrace Logo

Phase II Sunitinib Prog Met AIPC

NCT00599313 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-10-25

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

Conditions

Interventions

DRUG

Sunitinib

50 mg/day orally each of Days 1-28 of each 6 week cycle

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • US Oncology Research

    lead INDUSTRY

Principal Investigators

  • Guru Sonpavde, MD · US Oncology Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599313 on ClinicalTrials.gov